EXCELLENT OUTCOME OF CHILDREN/ADOLESCENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA TREATED WITH LMB-BASED CHEMOTHERAPY WITH RITUXIMAB. (October 2022)